Climb Bio, Inc. CLYM
NASDAQ · United States · Health Technology
$10.94-0.13 (-1.17%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and b
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.